Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same

US10533011B2 · kind B2 · utility

Assignee

• ACEA Therapeutics, Inc. · US

Inventors

• Long Mao · San Diego, US
• Jia Liu · San Diego, US
• Yile CHEN · Zhejiang, CN
• Yuning Hua · Hangzhou City, CN
• Kongen Dai · Hangzhou City, CN
• Yimei Bao · Hangzhou City, CN
• Bojie Weng · Zhejiang, CN
• Xiaopeng Mo · Zhejiang, CN
• Jian WU · Zhengzhou, CN
• Xiao Xu · Singapore, SG
• Wanhong Xu · Hangzhou City, CN
• Xiaobo Wang · San Diego, US

Key dates

• Filing date: Jun 30, 2016
• Grant date: Jan 14, 2020
• Expiry date: Jun 30, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are methods of making certain pyrrolopyrimidine derivatives, which are useful in the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3 (D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways, salts, polymorphs, and amorphous forms of said compounds, synthetic intermediates for preparing said compounds, and pharmaceutical compositions comprising said compounds and methods for making such compositions.